| Serial Number | 88241342 |
| Word Mark | TARSAL |
| Filing Date | Wednesday, December 26, 2018 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, October 19, 2020 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, January 21, 2020 |
| Goods and Services | Dietary supplements; Dietary supplements for controlling cholesterol; Dietary supplements for human consumption; Dietary supplements for urinary health; Dietary supplements in the nature of weight loss powders; Dietary supplements with a cosmetic effect; Dietary and nutritional supplements; Dietary and nutritional supplements for endurance sports; Dietary and nutritional supplements used for weight loss; Dietary fiber for use as an ingredient in the manufacture of dietary supplements; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical preparations for skin care; Pharmaceutical preparations for skin wounds; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, dantrolene sodium for injection; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Enzyme dietary supplements; Flaxseed dietary supplements; Flaxseed oil dietary supplements; Lecithin for use as a dietary supplement; Natural dietary supplements; Nutraceuticals for use as a dietary supplement; Nutritional and dietary supplements formed and packaged as bars; Ocular pharmaceuticals; Protein dietary supplements; Protein dietary supplements formed and packaged as bars; Soy isoflavone dietary supplements; all of the foregoing excludes goods specifically designed or marketed to treat issues related to the tarsus, or tarsal medical issues |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, January 16, 2019 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | NOT AVAILABLE |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 01 - Individual |
| Address | Oceanside, CA 92056 |
| Party Name | NOT AVAILABLE |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 01 - Individual |
| Address | Oceanside, CA 92056 |
| Party Name | Tarsal Pharmaceuticals Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Oceanside, CA 92056 |
| Party Name | NOT AVAILABLE |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 01 - Individual |
| Address | Oceanside, CA 92056 |
| Party Name | NOT AVAILABLE |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 01 - Individual |
| Address | Oceanside, CA 92056 |
| Party Name | Tarsal Pharmaceuticals Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Oceanside, CA 92056 |
| Event Date | Event Description |
| Monday, October 19, 2020 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, October 19, 2020 | ABANDONMENT - NO USE STATEMENT FILED |
| Tuesday, March 17, 2020 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, January 21, 2020 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, January 21, 2020 | PUBLISHED FOR OPPOSITION |
| Wednesday, January 1, 2020 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, December 17, 2019 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Monday, November 25, 2019 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, November 25, 2019 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, November 18, 2019 | ASSIGNED TO LIE |
| Monday, November 11, 2019 | NOTICE OF REVIVAL - E-MAILED |
| Monday, November 11, 2019 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, November 11, 2019 | PETITION TO REVIVE-GRANTED |
| Monday, November 11, 2019 | TEAS PETITION TO REVIVE RECEIVED |
| Wednesday, October 23, 2019 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Wednesday, October 23, 2019 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Wednesday, March 27, 2019 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, March 27, 2019 | NON-FINAL ACTION E-MAILED |
| Wednesday, March 27, 2019 | NON-FINAL ACTION WRITTEN |
| Tuesday, March 19, 2019 | ASSIGNED TO EXAMINER |
| Wednesday, January 16, 2019 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Saturday, December 29, 2018 | NEW APPLICATION ENTERED IN TRAM |